GlassScriptPhysician profile
Emma A Goldman
NPI 1093389801
$1,652.00
in general payments reported to CMS, 2019-2025
26 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $543 · 2023: $264 · 2024: $339 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785 · Education: $16.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.35 |
| Education | $16.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $192.68 | 2021-2022 | |
| Janssen Biotech, INC. | $172.54 | 2022-2024 | Stelara |
| Amgen INC. | $146.94 | 2021-2022 | |
| Lilly USA, LLC | $129.25 | 2022-2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $124.05 | 2022-2025 | Gattex, Entyvio |
| Abbvie INC. | $114.37 | 2021-2024 | |
| Fujifilm Healthcare Americas Corporation | $111.97 | 2023 | Utaswako Afp-L3 |
| Phathom Pharmaceuticals, INC. | $99.40 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.01 | 2023-2024 | Xifaxan, Plenvu |
| Innovation Technologies INC | $69.66 | 2025 | Irrisept |
| Horizon Therapeutics Plc | $55.14 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $42.69 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.12 | 2022 | |
| Grt US Holding, INC. | $36.15 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $27.61 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $27.00 | 2021-2022 | |
| Depuy Synthes Sales INC. | $24.72 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.77 | 2021 | |
| Avanos Medical | $22.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.33 | 2021 | |
| Sandoz INC. | $18.96 | 2023 | Hyrimoz |
| Braintree Laboratories, INC. | $17.82 | 2024 | Sutab, Suflave |
| Celltrion USA INC. | $16.15 | 2023 | Yuflyma |
| Nevro Corp. | $16.12 | 2021 | |
| Tela Bio, INC. | $13.98 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Nalu Medical, INC. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.